We are analyzing https://link.springer.com/article/10.1007/s40265-015-0434-6.

Title:
Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK | Drugs
Description:
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a proven benefit in terms of higher response rate, delaying progression and improvement of quality of life over palliative platinum-based chemotherapy. The most common adverse events (AEs) are gastrointestinal (GI) (diarrhoea and stomatitis/mucositis) and cutaneous (rash, dry skin and paronychia). These are usually mild, but if they become moderate or severe, they can have a negative impact on the patient’s quality of life (QOL) and lead to dose modifications or drug discontinuation. Appropriate management of AEs, including prophylactic measures, supportive medications, treatment delays and dose reductions, is essential. A consensus meeting of a UK-based multidisciplinary panel composed of medical and clinical oncologists with a special interest in lung cancer, dermatologists, gastroenterologists, lung cancer nurse specialists and oncology pharmacists was held to develop guidelines on prevention and management of cutaneous (rash, dry skin and paronychia) and GI (diarrhoea, stomatitis and mucositis) AEs associated with the administration of EGFR-TKIs. These guidelines detail supportive measures, treatment delays and dose reductions for EGFR-TKIs. Although the focus of the guidelines is to support healthcare professionals in UK clinical practice, it is anticipated that the management strategies proposed will also be applicable in non-UK settings.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Non-Profit & Charity
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't tell how the site generates income.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

patients, grade, article, pubmed, cancer, egfr, support, google, scholar, boehringer, ingelheim, management, clinical, egfrtki, aes, lung, egfrtkis, table, treatment, writing, stock, diarrhoea, dose, cas, pending, growth, phase, expert, factor, gefitinib, epidermal, receptor, events, adverse, advanced, rash, skin, paronychia, therapy, guidelines, oral, iii, spc, review, full, nsclc, cutaneous, potential, medicines, roche,

Topics {✒️}

gov/cancertopics/pdq/supportivecare/nutrition/healthprofessional/page4 egfr-inhibitor-induced skin reactions advanced egfr mutation-positive tyrosine kinase inhibitors epidermal growth article download pdf egfr-mutant advanced small-cell lung cancer small-cell lung cancer egfr-tki-related cutaneous aes wearing cotton-lined washing related subjects uk-based multidisciplinary panel patients taking egfr-tkis palliative platinum-based chemotherapy relieve mucositis-induced discomfort egfr-tki- related stomatitis egfr-tki-related aes initiating egfr-tki therapy discontinuing egfr-tki therapy egfr-tki-related diarrhoea egfr-tki- related paronychia egfr-tki-induced gi full access phase iii studies uk/conditions/mucositis/pages/treatment regimen-related gastrointestinal toxicities phase iii study egfr-mutant drug-related cutaneous aes product characterisitics—iressa starting egfr-tki treatment gene mutations egfr-tki-treated patients privacy choices/manage cookies phase ii trial current egfr-tki summary randomized controlled trial egfr-tkis trigger nat rev cancer lung cancer diagnoses skin-related aes including prophylactic measures mutation testing spanish expert panel prevent egfr-tki clinical nurse specialist erlotinib versus chemotherapy egfr inhibitors table 3 examples

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
         description:Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a proven benefit in terms of higher response rate, delaying progression and improvement of quality of life over palliative platinum-based chemotherapy. The most common adverse events (AEs) are gastrointestinal (GI) (diarrhoea and stomatitis/mucositis) and cutaneous (rash, dry skin and paronychia). These are usually mild, but if they become moderate or severe, they can have a negative impact on the patient’s quality of life (QOL) and lead to dose modifications or drug discontinuation. Appropriate management of AEs, including prophylactic measures, supportive medications, treatment delays and dose reductions, is essential. A consensus meeting of a UK-based multidisciplinary panel composed of medical and clinical oncologists with a special interest in lung cancer, dermatologists, gastroenterologists, lung cancer nurse specialists and oncology pharmacists was held to develop guidelines on prevention and management of cutaneous (rash, dry skin and paronychia) and GI (diarrhoea, stomatitis and mucositis) AEs associated with the administration of EGFR-TKIs. These guidelines detail supportive measures, treatment delays and dose reductions for EGFR-TKIs. Although the focus of the guidelines is to support healthcare professionals in UK clinical practice, it is anticipated that the management strategies proposed will also be applicable in non-UK settings.
         datePublished:2015-07-18T00:00:00Z
         dateModified:2015-07-18T00:00:00Z
         pageStart:1335
         pageEnd:1348
         sameAs:https://doi.org/10.1007/s40265-015-0434-6
         keywords:
            Epidermal Growth Factor Receptor
            Gefitinib
            Erlotinib
            Epidermal Growth Factor Receptor Mutation
            Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
            Pharmacotherapy
            Pharmacology/Toxicology
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-015-0434-6/MediaObjects/40265_2015_434_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-015-0434-6/MediaObjects/40265_2015_434_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-015-0434-6/MediaObjects/40265_2015_434_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-015-0434-6/MediaObjects/40265_2015_434_Fig4_HTML.gif
         isPartOf:
            name:Drugs
            issn:
               1179-1950
               0012-6667
            volumeNumber:75
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:R. Califano
               affiliation:
                     name:The Christie NHS Foundation Trust
                     address:
                        name:Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
                        type:PostalAddress
                     type:Organization
                     name:University Hospital of South Manchester
                     address:
                        name:Department of Medical Oncology, University Hospital of South Manchester, Manchester, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:N. Tariq
               affiliation:
                     name:The Christie NHS Foundation Trust
                     address:
                        name:Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S. Compton
               affiliation:
                     name:Guys and Thomas’s Hospital
                     address:
                        name:Department of Palliative Care, Guys and Thomas’s Hospital, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:D. A. Fitzgerald
               affiliation:
                     name:Salford Royal NHS Foundation Trust
                     address:
                        name:Department of Dermatology, Salford Royal NHS Foundation Trust, Salford, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:C. A. Harwood
               affiliation:
                     name:Barts Health NHS Trust and Barts and the London School of Medicine and Dentistry, Queen Mary University of London
                     address:
                        name:Centre for Cutaneous Research, Blizard Institute, Barts Health NHS Trust and Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:R. Lal
               affiliation:
                     name:Guys and Thomas’ Hospital
                     address:
                        name:Department of Medical Oncology, Guys and Thomas’ Hospital, London, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J. Lester
               affiliation:
                     name:Velindre Hospital
                     address:
                        name:Department of Clinical Oncology, Velindre Hospital, Cardiff, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:J. McPhelim
               affiliation:
                     name:Hairmyres Hospital
                     address:
                        name:Hairmyres Hospital, Glasgow, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:C. Mulatero
               affiliation:
                     name:St James Teaching Hospital
                     address:
                        name:Department of Medical Oncology, St James Teaching Hospital, Leeds, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S. Subramanian
               affiliation:
                     name:Royal Liverpool University Hospital
                     address:
                        name:Department of Gastroenterology, Royal Liverpool University Hospital, Liverpool, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:A. Thomas
               affiliation:
                     name:The Dudley Group NHS Foundation Trust, Russells Hall Hospital
                     address:
                        name:Pharmacy Department, The Dudley Group NHS Foundation Trust, Russells Hall Hospital, Dudley, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:N. Thatcher
               affiliation:
                     name:The Christie NHS Foundation Trust
                     address:
                        name:Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. Nicolson
               affiliation:
                     name:ANCHOR Unit-Clinic D, Aberdeen Royal Infirmary
                     address:
                        name:ANCHOR Unit-Clinic D, Aberdeen Royal Infirmary, Aberdeen, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
      description:Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a proven benefit in terms of higher response rate, delaying progression and improvement of quality of life over palliative platinum-based chemotherapy. The most common adverse events (AEs) are gastrointestinal (GI) (diarrhoea and stomatitis/mucositis) and cutaneous (rash, dry skin and paronychia). These are usually mild, but if they become moderate or severe, they can have a negative impact on the patient’s quality of life (QOL) and lead to dose modifications or drug discontinuation. Appropriate management of AEs, including prophylactic measures, supportive medications, treatment delays and dose reductions, is essential. A consensus meeting of a UK-based multidisciplinary panel composed of medical and clinical oncologists with a special interest in lung cancer, dermatologists, gastroenterologists, lung cancer nurse specialists and oncology pharmacists was held to develop guidelines on prevention and management of cutaneous (rash, dry skin and paronychia) and GI (diarrhoea, stomatitis and mucositis) AEs associated with the administration of EGFR-TKIs. These guidelines detail supportive measures, treatment delays and dose reductions for EGFR-TKIs. Although the focus of the guidelines is to support healthcare professionals in UK clinical practice, it is anticipated that the management strategies proposed will also be applicable in non-UK settings.
      datePublished:2015-07-18T00:00:00Z
      dateModified:2015-07-18T00:00:00Z
      pageStart:1335
      pageEnd:1348
      sameAs:https://doi.org/10.1007/s40265-015-0434-6
      keywords:
         Epidermal Growth Factor Receptor
         Gefitinib
         Erlotinib
         Epidermal Growth Factor Receptor Mutation
         Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
         Pharmacotherapy
         Pharmacology/Toxicology
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-015-0434-6/MediaObjects/40265_2015_434_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-015-0434-6/MediaObjects/40265_2015_434_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-015-0434-6/MediaObjects/40265_2015_434_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs40265-015-0434-6/MediaObjects/40265_2015_434_Fig4_HTML.gif
      isPartOf:
         name:Drugs
         issn:
            1179-1950
            0012-6667
         volumeNumber:75
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:R. Califano
            affiliation:
                  name:The Christie NHS Foundation Trust
                  address:
                     name:Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
                     type:PostalAddress
                  type:Organization
                  name:University Hospital of South Manchester
                  address:
                     name:Department of Medical Oncology, University Hospital of South Manchester, Manchester, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:N. Tariq
            affiliation:
                  name:The Christie NHS Foundation Trust
                  address:
                     name:Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S. Compton
            affiliation:
                  name:Guys and Thomas’s Hospital
                  address:
                     name:Department of Palliative Care, Guys and Thomas’s Hospital, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:D. A. Fitzgerald
            affiliation:
                  name:Salford Royal NHS Foundation Trust
                  address:
                     name:Department of Dermatology, Salford Royal NHS Foundation Trust, Salford, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:C. A. Harwood
            affiliation:
                  name:Barts Health NHS Trust and Barts and the London School of Medicine and Dentistry, Queen Mary University of London
                  address:
                     name:Centre for Cutaneous Research, Blizard Institute, Barts Health NHS Trust and Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:R. Lal
            affiliation:
                  name:Guys and Thomas’ Hospital
                  address:
                     name:Department of Medical Oncology, Guys and Thomas’ Hospital, London, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J. Lester
            affiliation:
                  name:Velindre Hospital
                  address:
                     name:Department of Clinical Oncology, Velindre Hospital, Cardiff, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:J. McPhelim
            affiliation:
                  name:Hairmyres Hospital
                  address:
                     name:Hairmyres Hospital, Glasgow, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:C. Mulatero
            affiliation:
                  name:St James Teaching Hospital
                  address:
                     name:Department of Medical Oncology, St James Teaching Hospital, Leeds, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S. Subramanian
            affiliation:
                  name:Royal Liverpool University Hospital
                  address:
                     name:Department of Gastroenterology, Royal Liverpool University Hospital, Liverpool, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:A. Thomas
            affiliation:
                  name:The Dudley Group NHS Foundation Trust, Russells Hall Hospital
                  address:
                     name:Pharmacy Department, The Dudley Group NHS Foundation Trust, Russells Hall Hospital, Dudley, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:N. Thatcher
            affiliation:
                  name:The Christie NHS Foundation Trust
                  address:
                     name:Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. Nicolson
            affiliation:
                  name:ANCHOR Unit-Clinic D, Aberdeen Royal Infirmary
                  address:
                     name:ANCHOR Unit-Clinic D, Aberdeen Royal Infirmary, Aberdeen, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Drugs
      issn:
         1179-1950
         0012-6667
      volumeNumber:75
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The Christie NHS Foundation Trust
      address:
         name:Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
         type:PostalAddress
      name:University Hospital of South Manchester
      address:
         name:Department of Medical Oncology, University Hospital of South Manchester, Manchester, UK
         type:PostalAddress
      name:The Christie NHS Foundation Trust
      address:
         name:Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
         type:PostalAddress
      name:Guys and Thomas’s Hospital
      address:
         name:Department of Palliative Care, Guys and Thomas’s Hospital, London, UK
         type:PostalAddress
      name:Salford Royal NHS Foundation Trust
      address:
         name:Department of Dermatology, Salford Royal NHS Foundation Trust, Salford, UK
         type:PostalAddress
      name:Barts Health NHS Trust and Barts and the London School of Medicine and Dentistry, Queen Mary University of London
      address:
         name:Centre for Cutaneous Research, Blizard Institute, Barts Health NHS Trust and Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
         type:PostalAddress
      name:Guys and Thomas’ Hospital
      address:
         name:Department of Medical Oncology, Guys and Thomas’ Hospital, London, UK
         type:PostalAddress
      name:Velindre Hospital
      address:
         name:Department of Clinical Oncology, Velindre Hospital, Cardiff, UK
         type:PostalAddress
      name:Hairmyres Hospital
      address:
         name:Hairmyres Hospital, Glasgow, UK
         type:PostalAddress
      name:St James Teaching Hospital
      address:
         name:Department of Medical Oncology, St James Teaching Hospital, Leeds, UK
         type:PostalAddress
      name:Royal Liverpool University Hospital
      address:
         name:Department of Gastroenterology, Royal Liverpool University Hospital, Liverpool, UK
         type:PostalAddress
      name:The Dudley Group NHS Foundation Trust, Russells Hall Hospital
      address:
         name:Pharmacy Department, The Dudley Group NHS Foundation Trust, Russells Hall Hospital, Dudley, UK
         type:PostalAddress
      name:The Christie NHS Foundation Trust
      address:
         name:Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
         type:PostalAddress
      name:ANCHOR Unit-Clinic D, Aberdeen Royal Infirmary
      address:
         name:ANCHOR Unit-Clinic D, Aberdeen Royal Infirmary, Aberdeen, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:R. Califano
      affiliation:
            name:The Christie NHS Foundation Trust
            address:
               name:Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
               type:PostalAddress
            type:Organization
            name:University Hospital of South Manchester
            address:
               name:Department of Medical Oncology, University Hospital of South Manchester, Manchester, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:N. Tariq
      affiliation:
            name:The Christie NHS Foundation Trust
            address:
               name:Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
               type:PostalAddress
            type:Organization
      name:S. Compton
      affiliation:
            name:Guys and Thomas’s Hospital
            address:
               name:Department of Palliative Care, Guys and Thomas’s Hospital, London, UK
               type:PostalAddress
            type:Organization
      name:D. A. Fitzgerald
      affiliation:
            name:Salford Royal NHS Foundation Trust
            address:
               name:Department of Dermatology, Salford Royal NHS Foundation Trust, Salford, UK
               type:PostalAddress
            type:Organization
      name:C. A. Harwood
      affiliation:
            name:Barts Health NHS Trust and Barts and the London School of Medicine and Dentistry, Queen Mary University of London
            address:
               name:Centre for Cutaneous Research, Blizard Institute, Barts Health NHS Trust and Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
               type:PostalAddress
            type:Organization
      name:R. Lal
      affiliation:
            name:Guys and Thomas’ Hospital
            address:
               name:Department of Medical Oncology, Guys and Thomas’ Hospital, London, UK
               type:PostalAddress
            type:Organization
      name:J. Lester
      affiliation:
            name:Velindre Hospital
            address:
               name:Department of Clinical Oncology, Velindre Hospital, Cardiff, UK
               type:PostalAddress
            type:Organization
      name:J. McPhelim
      affiliation:
            name:Hairmyres Hospital
            address:
               name:Hairmyres Hospital, Glasgow, UK
               type:PostalAddress
            type:Organization
      name:C. Mulatero
      affiliation:
            name:St James Teaching Hospital
            address:
               name:Department of Medical Oncology, St James Teaching Hospital, Leeds, UK
               type:PostalAddress
            type:Organization
      name:S. Subramanian
      affiliation:
            name:Royal Liverpool University Hospital
            address:
               name:Department of Gastroenterology, Royal Liverpool University Hospital, Liverpool, UK
               type:PostalAddress
            type:Organization
      name:A. Thomas
      affiliation:
            name:The Dudley Group NHS Foundation Trust, Russells Hall Hospital
            address:
               name:Pharmacy Department, The Dudley Group NHS Foundation Trust, Russells Hall Hospital, Dudley, UK
               type:PostalAddress
            type:Organization
      name:N. Thatcher
      affiliation:
            name:The Christie NHS Foundation Trust
            address:
               name:Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
               type:PostalAddress
            type:Organization
      name:M. Nicolson
      affiliation:
            name:ANCHOR Unit-Clinic D, Aberdeen Royal Infirmary
            address:
               name:ANCHOR Unit-Clinic D, Aberdeen Royal Infirmary, Aberdeen, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
      name:Department of Medical Oncology, University Hospital of South Manchester, Manchester, UK
      name:Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
      name:Department of Palliative Care, Guys and Thomas’s Hospital, London, UK
      name:Department of Dermatology, Salford Royal NHS Foundation Trust, Salford, UK
      name:Centre for Cutaneous Research, Blizard Institute, Barts Health NHS Trust and Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
      name:Department of Medical Oncology, Guys and Thomas’ Hospital, London, UK
      name:Department of Clinical Oncology, Velindre Hospital, Cardiff, UK
      name:Hairmyres Hospital, Glasgow, UK
      name:Department of Medical Oncology, St James Teaching Hospital, Leeds, UK
      name:Department of Gastroenterology, Royal Liverpool University Hospital, Liverpool, UK
      name:Pharmacy Department, The Dudley Group NHS Foundation Trust, Russells Hall Hospital, Dudley, UK
      name:Cancer Research UK Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
      name:ANCHOR Unit-Clinic D, Aberdeen Royal Infirmary, Aberdeen, UK

External Links {🔗}(159)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.35s.

LINK . SPRINGER . COM {}